MARKET

KALA

KALA

Kala Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.56
-0.09
-0.85%
After Hours: 10.56 0 0.00% 16:00 07/02 EDT
OPEN
10.91
PREV CLOSE
10.65
HIGH
10.98
LOW
10.31
VOLUME
589.34K
TURNOVER
--
52 WEEK HIGH
14.68
52 WEEK LOW
3.240
MARKET CAP
588.36M
P/E (TTM)
-4.1426
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KALA stock price target is 22.80 with a high estimate of 39.00 and a low estimate of 16.00.

EPS

KALA News

More
Hedge Funds Have Never Been This Bullish On Kala Pharmaceuticals, Inc. (KALA)
Insider Monkey · 06/23 16:01
Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders
Business Wire · 06/10 13:00
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
Is (KALA) Outperforming Other Medical Stocks This Year?
Zacks · 06/05 15:30
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13
J.P. Morgan: 2 Stocks to Buy for Over 40% Upside (And 1 to Avoid)
TipRanks · 06/02 13:41
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 06/02 11:45
Oppenheimer Maintains Outperform on Kala Pharmaceuticals, Raises Price Target to $21
Oppenheimer maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Outperform and raises the price target from $16 to $21.
Benzinga · 06/01 15:49
Aurinia Files NDA, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/29 02:52

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About KALA

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
More

Webull offers kinds of Kala Pharmaceuticals Inc stock information, including NASDAQ:KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.